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Nearly 12% of the population in the United States will be afflicted with a thyroid related
disorder during their lifetime. Common treatment approaches are tailored to the specific
disorder and include surgery, radioactive iodine ablation, antithyroid drugs, thyroid hormone
replacement, external beam radiation, and chemotherapy. Regenerative medicine endeav-
ors to combat disease by replacing or regenerating damaged, diseased, or dysfunctional
body parts. A series of achievements in pluripotent stem cell research have transformed
regenerative medicine in many ways by demonstrating “repair” of a number of body parts
in mice, of which, the thyroid has now been inducted into this special group. Seminal work
in pluripotent cells, namely embryonic stem cells and induced pluripotent stem cells, have
made possible their path to becoming key tools and biological building blocks for cell-based
regenerative medicine to combat the gamut of human diseases, including those affecting
the thyroid.
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INTRODUCTION
The thyroid gland synthesizes and releases two essential hor-
mones into the bloodstream. These hormones impact virtually
every tissue and cell in the body and play a role in regulating
a wide variety of biological processes, such as metabolism, brain
development, body temperature, weight, and much more. Thyroid
disease is fairly common with more than 12% of the population
experiencing a thyroid related condition at some point during
their lifetime in the United States alone (http://www.thyroid.org/
thyroid-events-education-media/about-hypothyroidism/). Thy-
roid disorders manifest in a variety of ways, which include:
hypothyroidism, hyperthyroidism, thyroid nodules, thyroiditis,
thyroid cancer, and goiters. Each disorder has a number of poten-
tial underlying causes. Untreated, a number of serious health
conditions, such as cardiovascular disease and osteoporosis may
result from thyroid disease. Even though nearly all thyroid diseases
are life-long afflictions, the good news is, with proper medical
attention they may be managed over the patient’s lifetime.
For a decade now, researchers have been exploring stem cell
technologies for the treatment of thyroid disorders (1–6). Success-
ful cell repair/replacement would eliminate a patient’s life-long
dependence on synthetic thyroid hormone replacement. At the
heart of this cell-based regenerative medicine reside pluripotent
stem cells (PSCs). PSCs are a special group of stem cell defined
by a few essential, yet distinguishing characteristics; (1) the abil-
ity to self-renew, (2) prolonged undifferentiated proliferation with
little or no karyotypic abnormalities, and (3) the potential to dif-
ferentiate into every cell lineage/type in the body. Recently, the
future of thyroid disease treatment took a giant step forward
when transplanted mouse embryonic stem cell (mESC) derived
thyroid follicles fostered symptomatic recovery in athyroidic
mice (4).
DERIVATION OF ES CELLS
Embryonic stem cells (ESCs) originate from the inner cell mass
(ICM) of blastocyst-stage embryos (7–9). Originally, mESC lines
were established by two similar, yet distinct, approaches. Evans
and Kaufman employed ovariectomy and hormonal stimulation
of pregnant female mice to impair implantation and induce devel-
opmental delay of embryos (7). Collected and cultured ICMs
developed into egg cylinder-like bodies that were picked, disso-
ciated, and passaged onto fibroblast feeders. Alternatively, Gail
Martin harvested early embryos from mated, superovulated female
mice (8). The trophectoderm was removed by immuno-surgery,
resulting in isolation of the ICM. It would not be until the late
1990s that the first human ESC lines would be created after cleav-
age stage embryos produced by in vitro fertilization were cultured
to the blastocyst stage (9). Original methods to culture ESCs sim-
plified the isolation of pluripotent cells by circumventing the need
to “convert” an embryo into a tumor in vivo. What’s more, it
made possible the isolation of ESCs from both non-inbred and
mutant mouse strains. Finally, these studies provided evidence of
a teratocarcinoma-derived growth factor essential for stimulating
non-differentiating proliferation of mESCs from cultured ICMs.
MAINTAINING ES CELLS IN VITRO
Once established, ESCs must be cultured under conditions that
promote undifferentiating proliferation. For the most part, gen-
eral media components, such as a feeder cells, Dulbecco’s Modi-
fied Eagle medium, and fetal bovine serum (FBS) are essentially
the same for standard culturing of virtually all ESCs. However,
species-specific ingredient requirements for non-differentiating
growth do exist. Differentiation-inhibiting activity (DIA, the key
cytokine secreted by feeders) was shown to be closely related struc-
turally and functionally to leukemia inhibitory factor (LIF) (10).
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Exogenous, recombinant LIF is capable of substituting for DIA,
thereby eliminating the need for feeders in mESC culturing.
The conditions for long-term culturing of human ESCs, how-
ever, differ from mouse in two fundamental ways. First, LIF plays
no apparent role in undifferentiated proliferation (11). Secondly,
exogenous bFGF is required when hESCs are cultured long-term
under serum-free conditions (12). However, feeder-free cultur-
ing on a matrix (matrigel or laminin) is capable of supporting
undifferentiated proliferation (13). Recently, hESC culturing was
transformed when a feeder-free culturing system demonstrated
prolonged cell culturing without loss of either pluripotency or dif-
ferentiation potential, or acquisition of karyotypic abnormalities,
even at clonal dilutions (14, 15).
When pluripotency promoting conditions are removed, ESCs
will differentiate. Under suitable conditions, cell lineages deriving
from the embryonic endoderm, mesoderm, and ectoderm will be
produced (16). Assessment of the differentiation potential of ESCs
is essential for their usefulness in research and future therapeu-
tic applications. Transplanting cells into immunodeficient mice
results in growth of a differentiated tumor (teratoma) composed
of all three germ layers. Alternatively, in vitro differentiation may
be initiated by allowing fully or partially dissociated ESCs to clus-
ter together under non-attachment conditions to form spherical
colonies, known as embryoid bodies (EBs) (16, 17). EBs may be
further differentiated by prolonged culturing following attach-
ment to a substrate. In vitro differentiation of ESCs into a broad
spectrum of lineages has been tremendously advanced by develop-
ment of many new suitable culture conditions and protocols. This
type of differentiation system has the potential of functioning as
an unlimited source of cells for cell-based regenerative medicine
and the treatment of a wide-range of diseases, including thyroid
disorders.
THYROID ONTOGENY AND DIFFERENTIATION OF THYROID
FOLLICULAR CELLS FROM ES CELLS
The thyroid gland is composed of two kinds of endocrine cells: thy-
roid follicular cells (TFC) and parafollicular C cells. TFCs, which
make up the bulk of the gland, are derived from foregut endoderm
and produce/secrete thyroid hormones T3 and T4. Parafollicular C
cells on the other hand, derive from the neuroectoderm and syn-
thesize calcitonin. During embryogenesis, the anteroposterior axis
of the foregut endoderm is laid out into organ-specific domains
that include the primordial thyroid, lung, pancreas, and liver (18,
19). Expression of defined sets of transcription factors at distinct
locations along the anteroposterior axis of the definitive endoderm
(DE) derived primitive gut demonstrates the first sign of regional
specification of organ domains (19). During early-to-mid embryo-
genesis, a small group of cells destined to become TFCs are found
in the primitive pharynx and are set apart by their co-expression of
Nkx2-1, Foxe, Pax8, and Hhex. Each of these genes is expressed in
other tissues outside of the thyroid; however, their co-expression is
restricted solely to the thyroid, where they direct thyroid organo-
genesis by establishing a thyroid-specific gene expression program
(20). TFCs are further characterized by their exclusive expression
of thyroglobulin (Tg ) and thyroperoxidase (TPO), as well as thy-
roid stimulating hormone receptor (TSHR) and sodium/iodide
symporter (NIS), which display extrathyroidal expression (20).
Evidence suggests that Nkx2-1 and Pax8 are mostly responsible
for driving thyroid-specific activation of Tg, TPO, and NIS genes
(21, 22). Despite its lack of specificity, thyroid agenesis in Nkx2-
1 knockout mice and pediatric hypothyroidism in humans born
withNKX2-1mutations further highlight the importance ofNkx2-
1 as a key regulator of thyroid organogenesis (23, 24). Similarly,
Pax8 knockout mice exhibit a total lack of TFCs and some cases of
congenital hypothyroidism in humans are found to be associated
with PAX8 mutations (25, 26).
In vitro differentiation of mESCs into TFCs was first demon-
strated by our laboratory in 2003 by the expression of thyroid
lineage markers in cultured EBs (1). It was also shown that con-
tinued Pax8 and TSHR expression in EB-derived monolayers
required TSH under serum-free conditions, whereasTg expression
was lost. A few years later, TFCs arranged in follicle-like clusters
were derived from an enriched population of ESCs expressing a
TSHR driven GFP when cultured on a basement membrane matrix
in the presence of TSH following insulin and insulin-like growth
factor-1 stimulation (2, 6). In order to more efficiently specify
TFCs in vitro, cells require methodically guided culturing con-
ditions conducive to initiate DE formation followed by anterior
foregut endoderm (AFE) induction. Although an efficient inducer
of mesoderm derived lineages; FBS is a poor endoderm inducer
(27). One noteworthy observation however was that restricting
mESC exposure to serum enhances DE associated gene expression
(27). Based on developmental findings in Xenopus, supplement-
ing medium with activin effectively promotes DE specification in
both mouse and human ESCs (27). Yet, DE produced from activin
induction alone withstands thyroid lineage specification, thus
requiring additional culturing modifications. NOGGIN (BMP sig-
naling antagonist) and SB-431542 (pharmacological inhibitor of
activin A/nodal and TGF-β signaling) emerged from a study test-
ing the ability of various morphogens and inhibitors to push DE
into AFE (28). Furthermore, addition of a growth factor cock-
tail composed of WNT3α, KGF, FGF10, BMP4, and EGF further
guided hESCs toward a ventral AFE fate (28). However, supple-
mentation of this cocktail with FGF2 was necessary for efficient
induction ofNkx2-1 in mESCs (29). Ultimately, these findings sug-
gest that thyroid competent cells (evidenced byNkx2-1,Foxa2, and
Pax8 expression) are effectively generated in endoderm progeni-
tors by stage-specific and time-dependent BMP/TGF-β inhibition
followed by combinatorial induction of BMP and FGF signal-
ing (29). Thus far, directed development of TFCs has only been
substantiated with mESCs and is yet uncertain whether current
protocols and methodologies would have similar developmental
consequences on hESCs.
Nkx2-1 and Pax8 were shown to synergize in activating expres-
sion from thyroid-specific promoter/enhancer driven constructs
in a hepatic cell line, however, endogenous thyroid-specific gene
expression was not detected (21). Two studies recently revealed
that Nkx2-1 and Pax8 overexpression in mESCs can direct differ-
entiation into TFCs in vitro and organize into three-dimensional
neo-follicles following TSH treatment (4, 5) without the need for
enrichment of lineage-directed cells using cell sorted fluorescent
reporter knock-in ESC lines (2). Remarkably, transient Nkx2-
1/Pax8 overexpression was capable of inducing follicle-like forma-
tion in vitro without early activin induced endoderm specification
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(Figure 1) (4). This approach obviates the complex, laborious cul-
ture requirements needed to direct differentiation of “unmodified”
ESCs. What remains to be seen is whether transient, insertion-less
strategies to ectopically expressNkx2-1/Pax8 with subsequent TSH
administration would be capable of eliciting the same outcome.
Perhaps thyroid lineage cells may be enriched by utilizing fluores-
cence activated cell sorting to capture lineage directed, unmodified
ESCs by interrogating cultured cells for expression of both NIS and
TSHR.
INDUCED PLURIPOTENT STEM CELLS
In 2006, the milestone discovery that fibroblasts could be con-
verted to PSCs, simply by forced expression of four transcription
factors (Oct4, Sox2, Klf4, and c-Myc ; collectively termed OSKM or
Yamanaka factors), took the research community by storm (30).
These iPSCs have broad applications, including: autologous cell-
based therapy; the modeling of genetic disorders; the study of
genetic variability; and functioning as a substrate for a variety of
targeted therapeutic screens (Figure 2). In addition to transform-
ing development and disease related research, iPSC technology
tore down technical and ethical barriers that inevitably mired
ESC-based regenerative medicine.
The Yamanaka factors reprogram somatic cells into ESC-like
cells by (1) silencing somatic and retroviral genes, (2) activat-
ing a network of pluripotency genes, and (3) inducing epigenetic
changes. When successfully reprogramed, iPSCs grow in tightly
packed, domed colonies, and resemble ESCs in morphology and
at the molecular and phenotypic levels; possess the ability to dif-
ferentiate into derivatives of the three embryonic germ layers; and
generate germline-competent chimeras. Table 1 shows the com-
parison between ESC and iPSC. The full developmental potential
of miPSCs was shown when reprogramed cells produced full-
term mice after injection into tetraploid blastocysts (31). Since its
inception, iPSC production has gone through a tremendous num-
ber of metamorphoses that have exploited and modified several
reprograming variables that include: donor cell type, reprogram-
ing cocktail, culture conditions, and integrative or non-integrative
delivery systems. Different cell types reprogram with different effi-
ciencies and kinetics. For instance, reprograming primary human
keratinocytes by OSKM transduction is 100 times more efficient
and twice as fast when compared to fibroblasts (32). Neural prog-
enitor cells represent another example because they are capable
of being reprogramed with only Oct4 and Klf4, due to their
endogenous expression of Sox2 (33).
Modifying or supplementing the core OSKM with other factors
or small molecules (35, 36) influencing pluripotency, proliferation,
and epigenetic remodeling have been shown to enhance the qual-
ity and efficiency of reprograming, in both mouse and human
iPSCs, as well as promote pluripotency maintenance during cul-
turing [reviewed in Ref. (37)]. Indeed, treatment of both mouse
and human fibroblasts with small-molecule chemicals in combi-
nation with genetic factors dramatically improved reprograming
efficiency and enabled reprograming with fewer genetic factors
(35, 38). Recently, it was discovered that ectopic expression of
the miR302/367 cluster, combined with Hdac2 suppression, can
directly and efficiently reprogram both mouse and human fibrob-
lasts without supplementation with any of the Yamanaka factors
(39).
Traditional retroviral delivery of reprograming factors admit-
tedly introduces an element of risk of tumorigenesis from trans-
planted iPSC-derived cells due to reactivation of transgenes and/or
insertional mutagenesis, thereby making them unsuitable for
therapeutic applications in humans. For this reason, researchers
have developed a variety of insertion-less approaches such as
non-integrating viruses, plasmids, small molecules, transposons,
recombinant proteins, episomal vectors, and modified RNAs to
generate iPSCs [reviewed in Ref. (40)]. Despite their lure, many
of these strategies are accompanied by limitations that cast a
shadow of doubt about their therapeutic safety. Nonetheless, these
and future approaches continue to bring the field of regenera-
tive medicine closer to safe, efficient iPSC generation for patient
treatment.
APPLICATION OF PLURIPOTENT STEM CELLS FOR
REGENERATIVE MEDICINE
Human ESCs and iPSCs have placed application of cell-based
regenerative medicine for the treatment of a host of diseases,
such as diabetes, Parkinson’s, and a variety of thyroid maladies,
FIGURE 1 | Schematic diagram of the protocol used for in vitro
differentiation of thyroid follicles from a tetracycline-inducible murine
Nkx2-1-Pax8 ESC line. LIF, leukemia inhibitory factor; rhTSH, recombinant
human thyroid stimulating hormone. Initial culturing of ESCs in hanging drops
(without LIF supplementation) allows for embryoid body differentiation.
Nkx2-1 and Pax8 are temporally induced by doxycycline, thereby directing
differentiation toward a thyrocyte fate. Forced expression of Nkx2-1/Pax8
results in robust thyroid stimulating hormone receptor expression, suggesting
cells are capable of responding to rhTSH. Therefore, the sequential treatment
of embryoid bodies with Dox-rhTSH dramatically enhances thyrocyte lineage
specification and the formation of follicle-like structures, which are
subsequently isolated for transplantation [Ref. (4)].
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FIGURE 2 | Applications of iPSC technology. Skin fibroblast-derived
iPSCs can produce thyroid follicles. These cells can be used for
(A) cell-based therapy, (B) disease modeling, and (C) drug discovery.
(A) Based on the demonstrated success of ESCs in rescuing thyroid
ablated mice, iPSCs derived thyroid follicles have incredible potential as a
cell replacement therapy for a variety of thyroid maladies. (B) iPSC lines
with genotypes characteristic of varied genetically based thyroid
diseases could provide an avenue to study disease mechanisms as well
as a screening system for evaluating pharmaceutical and recombinant
approaches aimed at treating those diseases. (C) iPSCs derived thyroid
follicles would enable easy quantification of drug effects on follicle
structure and function.
Table 1 | Comparison between ESC and iPSC.
iPS ES cells
Reported in humans Yes Yes
Embryos or donor oocytes
required
No Yes
Stemness marker expressed Yes Yes
Teratomas produced Yes Yes
Utility as a research tool Allows repeated
development
Allows the study of
development
Can be used as models for
human diseases
Yes Some
Can be used in a screen to
identify drugs
Yes Yes
Variable fates Likely Yes
Develop into specific human
tissues
To be shown Yes
Genetically match the patient Unknown No






Adapted from Nishikawa et al. (34). With permission from Macmillan Publish-
ers Ltd.
within reach. Today, the thyroid has now joined the list of body
parts now “repairable” in mice. Costagliola’s group rescued mice
afflicted with experimentally induced hypothyroidism by trans-
planting ESC-derived thyroid follicles (4). Ultimately, the chal-
lenge is to translate these findings into viable treatment strategies
for humans.
Embryonic stem cells are ethically controversial because human
embryos are destroyed for their derivation. Furthermore, concerns
exist about immune rejection of ESC-derived tissues following
transplantation into patients (30). Creation of genetically matched
ESCs through therapeutic cloning would make it possible to cir-
cumvent graft versus host disease (GvHD). However, use of ther-
apeutic cloning is still tainted by the destruction of an embryo,
requires substantial banking of donated oocytes, is technically
challenging, and is extremely inefficient. Oocytes derived from
lineage-directed PSCs represent a possible remedy to scarce oocyte
availability (41, 42). An alternative patient-specific cell source for
treatment of thyroid disease comes from the discovery of a resident
thyroid stem cell population (43–45).
Unlike ESCs, iPSCs are common and readily available, non-
controversial, capable of being produced from a patient’s cells in a
large number of academic and commercial laboratories, and repre-
sent virtually an endless supply of replacement tissues for the treat-
ment of trauma as well as a broad spectrum of diseases. Regardless
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of the reprograming approach, before autologous cells can be used
to regenerate/replace tissue lost or surgically removed due to dis-
ease, any underlying disease-causing genetic mutation(s) must be
known. Ideally, donor cells would be interrogated for the presence
of the genomic aberrations and then corrected after reprograming.
Idiopathic thyroid diseases suspected of being caused by genetic or
epigenetic defects can be surveyed for abnormalities with a variety
of methods [reviewed in Ref. (46)] and innovations in genome
editing, such as transcription activator-like effector nucleases, will
significantly advance targeted gene alteration in human stem cells
for therapeutic applications (47).
Before the practical application of PSCs in cell replacement
therapy can be realized, a number of issues need to be addressed.
The following talking points are by no means an exhaustive. (1)
Establishment of xenogenic-free and chemically defined cultur-
ing conditions to reduce culture variability and eliminate the
potential introduction of xenoantigens that elicit an immune
response. (2) Protocols for efficient induction of the appropriate
lineage. (3) Determination of maturation stage and the thera-
peutic cell dosage needed. (4) Stringent strategies for lineage
selection and/or purging of undifferentiated cells to reduce PSC
contamination of the graft, which can end in teratoma growth.
(5) Donor/recipient compatibility resulting in GvHD. (6) Do the
established differences between iPSCs and ESCs, such as epige-
netics (aberrant epigenetic memory as well as memory of the
donor cell) and mutational load translate into different therapeu-
tic outcomes? (7) Development of techniques for administering
the therapeutic cells into target location is vital to successful
treatment.
CONCLUSION
Diseases of the thyroid represent not only the most common
endocrine disorder but the most common autoimmune disease
(e.g., Hashimoto’s disease and Graves’ disease) as well (48). One
considerable obstacle standing in the way of successful applica-
tion of regenerative medicine approaches to treat many thyroid
disorders is an underlying autoimmunity like patients exhibit-
ing autoimmune thyroiditis type diseases. More than likely, cell
replacement would be doomed unless the underlying autoim-
munity is eliminated or suppressed. Cell-based immunotherapies
targeting a variety of malignancies are now in clinical prac-
tice. Assorted immune system lineages, such as dendritic, T,
and natural killer (NK) cells have been expanded in vitro then
infused back into patients (49–51). A recent immunotherapy study
using antigen-loaded dendritic cells yielded encouraging results
in patients diagnosed with medullary thyroid carcinoma as evi-
denced by disease stabilization and immunological response in
select patients (52). To augment this approach to combating neo-
plasias, hESC derived NK cells were shown to facilitate effective
tumor clearance in vivo (53). This finding suggests that hESCs,
and hiPSCs for that matter, are feasible cell sources for cancer
immunotherapy.
In summary, PSCs hold incredible curative and therapeutic
potential. Given the tremendous evolution in stem cell research
and advances in lineage-directed culturing, especially those induc-
ing TFCs, it is only a matter of time before cell-based regenerative
medicine becomes a treatment option for some thyroid disorders.
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